Practical Strategies for Improving Joint Health and Outcomes in Patients With Hemophilia A and B

This activity has expired.
Release Date: October 7, 2016
Expiration Date: October 7, 2017
Estimated Time to Complete Activity: 1 hour
Minimum System Requirements:
  • Internet Explorer 10 (or higher)
  • Mozilla Firefox 48 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 15.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Global Education Group.
Target Audience
This activity has been designed to meet the educational needs of hematologists, physicians, physician assistants, nurse practitioners, advanced practice registered nurses, registered nurses, physical therapists, social workers, and other specialists of the hemophilia treatment center (HTC) team, as well as clinicians interested in the treatment and management of patients with hemophilia A or hemophilia B.

Statement of Need/Program Overview
There are multiple barriers to achieving improved quality of life (QoL) in patients with hemophilia, especially those with existing joint damage. Repeated hemorrhaging into joints, particularly persons with severe hemophilia, can lead to the development of chronic joint disease. These individuals may suffer from joint pain, loss of range of motion, and crippling musculoskeletal deformity and disability, all of which impair their quality of life and have implications for employment, productivity, and psychosocial aspects.

Recently published, as well as ongoing randomized controlled clinical trials comparing prophylaxis with on-demand treatment, have definitely shown that prophylaxis reduces bleeding and improves joint outcomes in patients with severe hemophilia A or B. These trials have demonstrated that hemophilia patients on prophylactic treatment can experience an improvement in health related quality of life (HRQoL) through better protection from breakthrough bleeds, and the reduction in long-term damage complications, compared to episodic treatment.

With the CME/CE NetWorkShops series, these new findings can be brought to busy clinicians in the form of webcasts and organized group workshops at or near their Hemophilia Treatment Centers (HTCs). This enables healthcare professionals to view, analyze, and discuss key meeting findings with recognized hemophilia experts while gaining ideas on how to apply new learning to their own clinical practice.

Educational Objectives
After completing this activity, the participant should be better able to::
  • Review the clinical characteristics and implications of joint bleeding in patients with hemophilia
  • Implement strategies for assessing pain as both a marker for bleeding and a measure of the effectiveness of a therapeutic intervention
  • Assess prophylactic and on-demand treatment regimens in terms of improving joint health and quality of life in patients with hemophilia
  • Explain the importance of counseling patients/caregivers about their therapy as well as the importance of adherence to the treatment regimen
  • Evaluate clinical trial data for new and emerging long-acting factor VIII and IX concentrates used for treating patients with hemophilia A and B
  • Implement individualized treatment plans which protect hemophilia patients from developing spontaneous and activity-induced acute bleeding complications and contribute to an improved quality of life
Presenting Faculty
Cindy Leissinger, MD
Professor of Medicine, Pediatrics
Tulane University School of Medicine
New Orleans, Louisiana

Planning Committee
Miguel A. Escobar, MD - Chairperson
Professor of Medicine & Pediatrics
Division of Hematology
University of Texas Health Science Center
Gulf States Hemophilia & Thrombophilia Center
Houston, Texas

Cindy Leissinger, MD
Professor of Medicine, Pediatrics
Tulane University School of Medicine
New Orleans, Louisiana

Doris Quon, MD, PhD
Medical Director
Orthopaedic Hemophilia Treatment Center
Orthopaedic Institute for Children
Los Angeles, CA

John Urgo, RN, BSN
Program Nurse Coordinator
Hemophilia and Thrombophilia Center
Rush University Medical Center
Chicago, Illinois

Christopher Walsh, MD, PhD
Associate Professor
Director Hematology Treatment Center
Division of Hematology and Oncology
ICAHN School of Medicine at Mount Sinai
New York, New York

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global), and Educational Concepts in Medicine (ECM). Global is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation
Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit
A statement of credit will be issued only upon receipt of a completed activity evaluation form and application for credit. Certificates will be downloadable upon completion of the activity).

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or

Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty Planners/ Presenters Reported Financial Relationship
Miguel A. Escobar, MD Consulting/Independent Contractor: BPL, Kedrion, Bayer, Baxalta, Novo Nordisk, NHF, Pfizer, Biogen
Cindy Leissinger, MD Grant/Research Support: Baxalta Advisory Board: Novo Nordisk, Baxalta, Biogen, CSL Behring, Kedrion, Bayer, Roche.
Doris Quon, MD, PhD Honoraria: Baxalta, Bayer, Biogen, NovoNordisk; Speaker’s Bureau: Baxalta, Biogen, CSL, NovoNordisk, Grifols
John Urgo, RN Nothing to disclose
Christopher Walsh, MD Consulting Fees: Bayer, Baxalta, CSI, Behring, Pfizer, Roche, Alnylam; Speaker’s Bureau: Novo Nordisk, Baxalta

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Global: Ashley Marostica, RN, MSN, Amanda Glazar, PhD, Andrea Funk, Laura Gilsdorf Nothing to disclose
ECM: Patrick J. Crowley, MBA, President; Jodi Andrews, BS, Vice President, Operations, Jo-Ann Angelucci, BA, Program Director; Helen Morfit, BS, Program Director; Emma Hitt Nichols, PhD, ELS Senior Medical Writer Nothing to disclose

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and ECM do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information
There is no fee for this educational activity.

This activity is supported by an educational grant from Biogen Idec, Grifols and BioRx.